We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Supreme Court will not make a determination on Ranbaxy’s challenge of the validity and enforceability of Pfizer’s main Lipitor patent, the court said.